js","9897","static/chunks/9897-96ec494a15704266.js","4005","static/chunks/4005-f97caa47699c0d92.js","9180","static/chunks/9180-141aeb8e4de0fb19.js","855","static/chunks/855-cf19c6c21b03f067.js","5208","static/chunks/5208-62bc554de8278993.js","1094","static/chunks/1094-e2bede973ee0fcba.js","261","static/chunks/261-62d59822d4693e14.js","105","static/chunks/105-0cf779e7b5058905.js","3204","static/chunks/3204-771fe8926763857e.js","1416","static/chunks/1416-2c3ea9586cfb2d8c.js","5657","static/chunks/5657-7d7ce34b53a75bbe.js","3864","static/chunks/3864-e65f5ab7d1e2b87f.js","6936","static/chunks/6936-95130c4492d838b4.js","8678","static/chunks/8678-a0502ad698b1d653.js","9781","static/chunks/9781-cfd3d6d9018cf1de.js","5181","static/chunks/5181-7cb9d448d4c5f6b5.js","1730","static/chunks/1730-e164aa8f11e16aba.js","7755","static/chunks/7755-a0da8883abfcfd81.js","7946","static/chunks/7946-aed52829e81f011b.js","8422","static/chunks/8422-2eeeb4781ba7854c.js","9077","static/chunks/9077-b99ded772bea5001.js","4586","static/chunks/4586-eae7a152abb3202c.js","1324","static/chunks/1324-0939666a4c952298.js","7107","static/chunks/7107-4c801ae286d6095d.js","4755","static/chunks/4755-3c4b0c8adb59bcb9.js","5458","static/chunks/app/dashboard/episodes/%5Bid%5D/page-c181d169ce19ca2c.js"],"EpisodeRecommend"] 24:T73b,

With political uncertainty overshadowing market sentiment going into 2025, BioCentury’s editorial team assesses the bull and bear arguments for biotech in the New Year on the BioCentury This Week podcast’s Public Markets Preview. Will continued uncertainty drive biotech sentiment in the coming months, or will the bear arguments fail to manifest, stymied by M&A and other positive factors?
In the second part of the 2025 Preview, BioCentury’s editors highlight some of the key catalysts in bispecifics, immunology and inflammatory (I&I), new

Ep. 274 - 2025 Biotech Preview: Markets, Catalysts and AI

BioCentury This Week